Cargando…
Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report
OBJECTIVE: To develop clinically meaningful improvement thresholds in both the 17-item and the 6-item Hamilton Rating Scale for Depression (HRSD) total scores in depressed outpatients. METHODS: The post-hoc analysis included all adult outpatients with non-psychotic major depressive disorder in the S...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290193/ https://www.ncbi.nlm.nih.gov/pubmed/34295161 http://dx.doi.org/10.2147/NDT.S305331 |
_version_ | 1783724445441982464 |
---|---|
author | Rush, Augustus John South, Charles Jain, Shailesh Agha, Raafae Zhang, Mingxu Shrestha, Shristi Khan, Zershana Hassan, Mudasar Trivedi, Madhukar H |
author_facet | Rush, Augustus John South, Charles Jain, Shailesh Agha, Raafae Zhang, Mingxu Shrestha, Shristi Khan, Zershana Hassan, Mudasar Trivedi, Madhukar H |
author_sort | Rush, Augustus John |
collection | PubMed |
description | OBJECTIVE: To develop clinically meaningful improvement thresholds in both the 17-item and the 6-item Hamilton Rating Scale for Depression (HRSD) total scores in depressed outpatients. METHODS: The post-hoc analysis included all adult outpatients with non-psychotic major depressive disorder in the STAR*D trial who entered and exited the first treatment step (up to 14 weeks of citalopram) with a complete set of study measures at baseline and exit and at least one post-baseline measure. Within-patient change and linear regression anchor-based analyses were conducted to define meaningful and substantial changes in the HRSD(17) and HRSD(6) using three patient-reported outcomes [Work and Social Adjustment Scale (WSAS), Quality of Life Enjoyment and Satisfaction-Short Form (Q-LES-Q-SF); Mini-Q-LES-Q] obtained at baseline and exit from the first treatment step in STAR*D. RESULTS: Linear regression analyses identified a meaningful change threshold for the HRSD(17) as 3.9 [3.7–4.1] [lower, upper 95% CI] and a substantial change as 7.8 [7.4–8.3] with the WSAS. Analogous thresholds based on the Q-LES-Q-SF were 5.8 [5.5–6.1] and 11.6 [11.0–12.2], respectively, and 4.9 [4.7–5.2] and 9.9 [9.3–10.4] for the Mini-QLES-Q, respectively. For the HRSD(6), linear regression analyses with the WSAS identified a meaningful change as 2.2 [2.1–2.4], while a substantial change was 4.5 [4.2–4.7]. Analogous figures based on the Q-LES-Q-SF were 3.2 [3.0–3.4] and 6.4 [6.1–6.8]. Similarly, based on the Mini-QLESQ, results were 2.8 [2.6–2.9] and 5.6 [5.3–5.9]. For both the HRSD(17) and the HRSD(6), within-patient analyses produced less precise estimates of the same change thresholds with substantial overlap between groups. Based on the WSAS, a clinically meaningful change in the HRSD(17) total score was 9.6 (SD = 6.5), while a substantial change was 15.0 (SD = 6.7). Analogous change thresholds based on the Q-LESQ-SF were 12.9 (SD = 6.2) and 16.8 (SD = 6.4), respectively. For the Mini-Q-LES-Q, thresholds were 10.9 (SD = 6.5) and 16.1 (SD = 6.2). CONCLUSION: A 4–6 point change in the HRSD(17) is clinically meaningful; a 7–12 point change is clinically substantial. For the HRSD(6), analogous estimates were 2–3 and 4–7 point changes, respectively. |
format | Online Article Text |
id | pubmed-8290193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82901932021-07-21 Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report Rush, Augustus John South, Charles Jain, Shailesh Agha, Raafae Zhang, Mingxu Shrestha, Shristi Khan, Zershana Hassan, Mudasar Trivedi, Madhukar H Neuropsychiatr Dis Treat Clinical Trial Report OBJECTIVE: To develop clinically meaningful improvement thresholds in both the 17-item and the 6-item Hamilton Rating Scale for Depression (HRSD) total scores in depressed outpatients. METHODS: The post-hoc analysis included all adult outpatients with non-psychotic major depressive disorder in the STAR*D trial who entered and exited the first treatment step (up to 14 weeks of citalopram) with a complete set of study measures at baseline and exit and at least one post-baseline measure. Within-patient change and linear regression anchor-based analyses were conducted to define meaningful and substantial changes in the HRSD(17) and HRSD(6) using three patient-reported outcomes [Work and Social Adjustment Scale (WSAS), Quality of Life Enjoyment and Satisfaction-Short Form (Q-LES-Q-SF); Mini-Q-LES-Q] obtained at baseline and exit from the first treatment step in STAR*D. RESULTS: Linear regression analyses identified a meaningful change threshold for the HRSD(17) as 3.9 [3.7–4.1] [lower, upper 95% CI] and a substantial change as 7.8 [7.4–8.3] with the WSAS. Analogous thresholds based on the Q-LES-Q-SF were 5.8 [5.5–6.1] and 11.6 [11.0–12.2], respectively, and 4.9 [4.7–5.2] and 9.9 [9.3–10.4] for the Mini-QLES-Q, respectively. For the HRSD(6), linear regression analyses with the WSAS identified a meaningful change as 2.2 [2.1–2.4], while a substantial change was 4.5 [4.2–4.7]. Analogous figures based on the Q-LES-Q-SF were 3.2 [3.0–3.4] and 6.4 [6.1–6.8]. Similarly, based on the Mini-QLESQ, results were 2.8 [2.6–2.9] and 5.6 [5.3–5.9]. For both the HRSD(17) and the HRSD(6), within-patient analyses produced less precise estimates of the same change thresholds with substantial overlap between groups. Based on the WSAS, a clinically meaningful change in the HRSD(17) total score was 9.6 (SD = 6.5), while a substantial change was 15.0 (SD = 6.7). Analogous change thresholds based on the Q-LESQ-SF were 12.9 (SD = 6.2) and 16.8 (SD = 6.4), respectively. For the Mini-Q-LES-Q, thresholds were 10.9 (SD = 6.5) and 16.1 (SD = 6.2). CONCLUSION: A 4–6 point change in the HRSD(17) is clinically meaningful; a 7–12 point change is clinically substantial. For the HRSD(6), analogous estimates were 2–3 and 4–7 point changes, respectively. Dove 2021-07-14 /pmc/articles/PMC8290193/ /pubmed/34295161 http://dx.doi.org/10.2147/NDT.S305331 Text en © 2021 Rush et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Rush, Augustus John South, Charles Jain, Shailesh Agha, Raafae Zhang, Mingxu Shrestha, Shristi Khan, Zershana Hassan, Mudasar Trivedi, Madhukar H Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report |
title | Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report |
title_full | Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report |
title_fullStr | Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report |
title_full_unstemmed | Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report |
title_short | Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report |
title_sort | clinically significant changes in the 17- and 6-item hamilton rating scales for depression: a star*d report |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290193/ https://www.ncbi.nlm.nih.gov/pubmed/34295161 http://dx.doi.org/10.2147/NDT.S305331 |
work_keys_str_mv | AT rushaugustusjohn clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT southcharles clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT jainshailesh clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT agharaafae clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT zhangmingxu clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT shresthashristi clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT khanzershana clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT hassanmudasar clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport AT trivedimadhukarh clinicallysignificantchangesinthe17and6itemhamiltonratingscalesfordepressionastardreport |